ERBB2 and breast carcinoma: Although NET is accepted as an alternative treatment for ERBB2-negative breast cancers that are strongly HR positive, no study has previously compared the association with OS in NACT and NET groups.15,18,51,52,53 Our findings indicate that compared with the NACT group, the NET group had a higher risk of all-cause death with an aHR of 2.67 (95% CI, 1.95-3.51) (Table 2).